{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:29:58Z","timestamp":1793035798113,"version":"4.5.0"},"reference-count":70,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Covenant University Center for Research, Innovation, and Discovery","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Prostate cancer (PCa) stands as one of the primary cancer diseases affecting male health and represents the principal reason behind death when metastasis develops during late-stage disease. The spread of prostate cancer from its initial site demands intricate molecular interactions through signaling pathways which permit cancer cells to break their attachment to the original tumor mass and form secondary tumor sites in distant organs. Prostate cancer metastasis depends heavily on three main molecular pathways which include the PI3K\/AKT signaling cascade along with Wnt\/\u03b2-catenin pathway and epithelial-mesenchymal transition (EMT) signaling mechanisms. The deregulation of these signaling pathways creates strong contributions toward prostate cancer spread during metastasis and reduction of response to standard treatment methods. Presently available androgen deprivation therapy and chemotherapy have proven successful to some extent yet insufficient for effective treatment of both castration-resistant prostate cancer (CRPC) and metastatic disease. The development of therapies which block AKT signaling combined with Wnt signaling inhibition and reversal of EMT processes creates new treatment opportunities for better cancer outcome results. The combined use of immunotherapy with personalized medicine along with liquid biopsy technologies will improve therapeutic effects by enabling real-time tracking of disease evolution and treatment response. This analysis investigates the molecular processes that drive prostate cancer metastasis and the present therapeutic solutions and the upcoming therapies that try to block these pathways. Numerous treatment approaches and precision medicine strategies combining the integrated treatment approaches may lead to improved therapeutic benefit with fewer adverse effects while delivering more personalized and effective care. This review will majorly focus on the molecular pathways and preclinical treatment options that support metastatic prostate cancer, but briefly outline the clinical progress that is currently shaping the precision therapeutic models.<\/jats:p>","DOI":"10.1177\/15330338251408321","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:06:07Z","timestamp":1778501167000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Drivers of Prostate Cancer Metastasis: Emerging Targets for Precision Therapy"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-1416","authenticated-orcid":false,"given":"Emeka Eze Joshua","family":"Iweala","sequence":"first","affiliation":[{"name":"Covenant University"},{"name":"Covenant University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6106-6533","authenticated-orcid":false,"given":"Chukwuemeka Pius","family":"Nwokoro","sequence":"additional","affiliation":[{"name":"Covenant University"},{"name":"Covenant University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"e_1_3_4_2_2","article-title":"The association of steroid 5-alpha reductase type-II gene polymorphisms (A49T and V89L) with prostate cancer risk in African population: a systematic review and meta-analysis","volume":"26","author":"Ayeni TO","year":"2024","unstructured":"Ayeni TO, Bajepade TI, Akanni MH, Pirisola AJ, Oluwajembola AM, Chinedu SN. The association of steroid 5-alpha reductase type-II gene polymorphisms (A49T and V89L) with prostate cancer risk in African population: a systematic review and meta-analysis. Sci Afr. 2024;26:e02370.","journal-title":"Sci Afr"},{"key":"e_1_3_4_3_2","first-page":"101517","article-title":"Age-sex-specific burden of urological cancers attributable to risk factors in China and its provinces, 1990\u20132021, and forecasts with scenarios simulation: A systematic analysis for the Global Burden of Disease Study 2021","volume":"56","author":"Xue M","year":"2025","unstructured":"Xue M, Guo W, Zhou Y, et al. Age-sex-specific burden of urological cancers attributable to risk factors in China and its provinces, 1990\u20132021, and forecasts with scenarios simulation: A systematic analysis for the Global Burden of Disease Study 2021. Lancet Reg Health West Pac. 2025;56:101517.","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00714"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241290029"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-022-00702-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124507"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/life11101099"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100747"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2015.04.011"},{"issue":"4","key":"e_1_3_4_11_2","first-page":"318","article-title":"Alterations in TGF\u03b2 signaling during prostate cancer progression","volume":"9","author":"Thompson-Elliott B","unstructured":"Thompson-Elliott B, Johnson R, Khan SA. Alterations in TGF\u03b2 signaling during prostate cancer progression. Am J Clin Exp Urol. 2021 Aug 25 [cited 2025 Apr 30];9(4):318. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8446771\/","journal-title":"Am J Clin Exp Urol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2279235"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-051222-122423"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2011.85"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2015.1016686"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666141211120326"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101118"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.01.013"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194985"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109320"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.2174\/15680096113136660102"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22790"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15686"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.010"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2018.9"},{"issue":"1","key":"e_1_3_4_27_2","first-page":"1","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He Y","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):1\u201317. https:\/\/www.nature.com\/articles\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"issue":"6","key":"e_1_3_4_29_2","article-title":"The Akt pathway in oncology therapy and beyond","volume":"53","author":"Nitulescu G","year":"2018","unstructured":"Nitulescu G, Van De Venter M, Nitulescu G, et al. The Akt pathway in oncology therapy and beyond. Int J Oncol. 2018;53(6).","journal-title":"Int J Oncol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00762-6"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01563-4"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.02.008"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.002"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007898"},{"issue":"1","key":"e_1_3_4_35_2","article-title":"Wnt\/\u03b2-catenin signal transduction pathway in prostate cancer and associated drug resistance","volume":"12","author":"Wang C","year":"2021","unstructured":"Wang C, Chen Q, Xu H. Wnt\/\u03b2-catenin signal transduction pathway in prostate cancer and associated drug resistance. Discov Oncol. 2021;12(1).","journal-title":"Discov Oncol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.206"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-136994"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0289"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026057402945"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2442067"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101134"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/EdBook_AM.2013.33.e395"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70354"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00218-4"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163949"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115676"},{"issue":"8","key":"e_1_3_4_47_2","first-page":"1110","article-title":"A new wave of targeting \u201cundruggable\u201d wnt signaling for cancer therapy: challenges and opportunities","volume":"12","author":"Park WJ","year":"2023","unstructured":"Park WJ, Jong Kim M. A new wave of targeting \u201cundruggable\u201d wnt signaling for cancer therapy: challenges and opportunities. Natl Cent Biotechnol Inf. 2023;12(8):1110.","journal-title":"Natl Cent Biotechnol Inf"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14038"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314239110"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00095"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4455"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07469"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-021-01321-x"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133338"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01347-8"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0298"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318282635a"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101232"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.12.003"},{"key":"e_1_3_4_60_2","volume-title":"Prostate cancer","author":"Leslie SW","year":"2023","unstructured":"Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE. Prostate cancer. Nih.gov. StatPearls Publishing; 2023, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470550\/."},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116850"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0714"},{"key":"e_1_3_4_63_2","article-title":"Blocking the WNT\/\u03b2-catenin pathway in cancer treatment: pharmacological targets and drug therapeutic potential","author":"Zhao X","year":"2024","unstructured":"Zhao X, Ma Y, Luo J, et al. Blocking the WNT\/\u03b2-catenin pathway in cancer treatment: pharmacological targets and drug therapeutic potential. Heliyon. 2024:e35989.","journal-title":"Heliyon"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104604"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2018.05.004"},{"key":"e_1_3_4_66_2","first-page":"100778","article-title":"Emerging frontiers in nanomedicine targeted therapy for prostate cancer","volume":"37","author":"Adekiya TA","year":"2023","unstructured":"Adekiya TA, Owoseni O. Emerging frontiers in nanomedicine targeted therapy for prostate cancer. Cancer Treat Res Commun. 2023;37:100778.","journal-title":"Cancer Treat Res Commun"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.003"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115078"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00041"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251408321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338251408321","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251408321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:06:16Z","timestamp":1778933176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338251408321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"alternative-id":["10.1177\/15330338251408321"],"URL":"https:\/\/doi.org\/10.1177\/15330338251408321","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"15330338251408321"}}